FOURLIGHT-1
Start here
Three abstracts presented at ESMO 2026 address the treatment of HR-positive, HER2-negative advanced breast cancer after progression on CDK4/6 inhibitors, one of the most pressing open questions in this setting. The studies evaluate different combination strategies: one with atirmociclib, one with abemaciclib, and one pairing giredestrant with another agent. Each explores whether these regimens can offer a viable next line of therapy for patients whose disease has stopped responding to the current standard. As conference abstracts, the findings are early and full data presentations are expected to clarify efficacy and safety. How these options compare with existing post-CDK4/6 approaches, and which patients are most likely to benefit from each, remains unresolved.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPick2026 ESMO Abstracts Focus on Next Treatment After CDK4/6 Inhibitor Progression in Advanced Breast Cancer
Three 2026 ESMO abstracts address subsequent therapy for HR+/HER2− advanced breast cancer after progression on CDK4/6 inhibitors, covering atirmociclib, abemaciclib, and giredestrant combination regimens respectively.
- x.comFourLight-1 #ESMO26
- x.comFOURLIGHT-1
Heat trend for this story
Heat now 71·Peak in the comparable set 157 (Oct 24 18:00)·Change over 24h in the comparable set -38%·Participants now 25
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.